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doi:10.1016/j.jfma.2012.02.020Background/Purpose: Cytomegalovirus (CMV) disease constitutes a serious complication after
stem cell transplantation and has been treated by adoptive transfer of donor-derived CMV-
specific CD8þ T cells. CMV-specific CD8þ T cells were selected by multimers, and the technol-
ogies may alter the function of these T cells. Therefore, here we evaluated the impact of
multimer reagents on the function of CD8þ T lymphocytes.
Methods: CMV-specific CD8þ T cells were purified from the peripheral blood of donors using
tetra- and streptamer technologies. The functional status of purified CMV-specific CD8þ T cells
was assessed by multiparametric immunophenotyping and carboxyfluorescein succinimidyl
ester proliferation assays as well as by enzyme-linked immunospot assays.
Results: A similar percentage of CMV-specific CD8þ T cells could be purified by both tetra-
(90%) and streptamer (92%) technologies. That constitutes a 30- to 50-fold concentration of
CMV-specific CD8þCD45RAþCCR7effector T cells. Selected cells secreted interferon-gamma
and granzyme B upon stimulation with CMVpp65 peptide, thus demonstrating their function-
ality.
Conclusion: Our study demonstrated that both tetra- and streptamer technologies can be used
to purify CMV-specific cytotoxic CD8þ T cells for adoptive T-cell transfer. Both multimert of Hematology, The Affiliated Zhongda Hospital of Southeast University, Dingjiaqiao 87, 210009
com (B.-A. Chen).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
Streptamer versus tetramer-based selection 339technologies did not have any negative influence on the proliferation of selected T cells.
Importantly, streptamer technology is available at good manufacturing practice level.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Cytomegalovirus (CMV) reactivation can not only lead to
severe complications, but also induce or increase graft-
versus-host disease (GVHD) after allogeneic stem cell
transplantation (allo-HSCT).1e3 Prophylactic and preemp-
tive treatment with antiviral drugs has been applied to
reduce the incidence of CMV reactivation.4,5 CMV-specific
CD8þ T cells were demonstrated to be of crucial impor-
tance for preventing or at least limiting CMV reactivation.6
Therefore, adoptive transfer of virus-specific CD8þ T cells
was developed to prevent and treat both CMV reactivation
and disease. The groups around Riddell et al7 and Einsele
et al8 had demonstrated that virus-specific CD8þ T cells
could result in both an antivirus effect and a reduction of
GVHD. Both groups exploited the complex and cumbersome
technology of T-cell cloning, which is hardly feasible at the
majority of bone marrow transplantation centers. There-
fore, Cobbold et al9 used Human Leukocyte Antigen (HLA)e
peptide tetramers to purify CMV-specific CD8þ T cells from
CMV-seropositive donors and transferred them directly into
the recipient. Recently, the novel streptamer technology
has been developed for the detection and purification of
antigen-specific T cells.10 Currently, our group is investi-
gating on CMV-specific CD8þ T cells from CMV-seropositive
donors using the streptamer technology. Both tetramers
and streptamers can stain CMV-specific CD8þ T cells.11,12
Therefore, they might also facilitate the clinical applica-
tion of adoptive CMV-specific CD8þ T cells transfer regi-
mens.9,10 However, both multimers might also alter the
functional status of CMV-specific CD8þ T cells. In this study,
we therefore assessed the impact of tetramers and strep-
tamers on the function of CMV-specific CD8þ T
lymphocytes.
Methods
Samples from healthy donors
All samples were taken from HLA-A2þ healthy donors after
informed consent was obtained in accordance with the
Declaration of Helsinki. The study was approved by the local
Ethical Committee (HV-2009-0004). Peripheral blood mono-
nuclear cells (PBMCs) were isolated by FicolleBiocoll sepa-
ration solution (Biochrom, Berlin, Germany) density gradient
centrifugation from EDTA (Delta-Pharma, Pfullingen,
Germany) anticoagulated blood buffy coat preparations
from healthy donors. The viability of PBMCs was always
>95%, as determined by Trypan blue staining (Trypan Blue
Solution 0.4%, Sigma-Aldrich, Munich, Germany). Viable cells
were quantified using a Neubauer chamber (Zeiss, Oberko-
chen, Germany). For cellular assays, Ficoll-separated PBMCs
were tested freshly or cryopreserved in RPMI 1640 containing20% human AB serum and 10% dimethyl sulfoxide (Merck,
Darmstadt, Germany), and stored in liquid nitrogen.
Flow cytometry for multiparametric
immunophenotyping
To evaluate the percentage of the CMV-specific CD8þ T cells,
samples were analyzed by flow cytometry. CD8þ T cells were
detected using peridinin chlorophyll (PerCP)-labeled anti-
CD8 antibodies. CMV-specific CD8þ T cells were detected by
using the conjugate of CMVpp65 peptideeMajor Histocom-
patibility Complex (MHC) class I complex with Strep-Tactin-
PE. HLA-A2*0201/CMV peptide streptamer*PE was specifi-
cally synthesized at IBA GmbH (Go¨ttingen, Germany). For
staining, the cellswere incubatedwith theHLA-A2*0201/CMV
peptide streptamer*PE for 45 minutes at 4C in the dark.
CMVeMHC complex was used at a concentration of 0.2 mg per
1 106 cells in 100 mL per test. For multiparametric analysis,
anti-CD8*PerCP, anti-CCR7*APC, anti-CD45RA*FITC, anti-
CD69*APC, anti-CD107a*FITC, anti-CD137*APC, and anti-
CD28*FITC (BD, Heidelberg, Germany) antibodies were
added at 4C for 20 minutes in the dark. After washing twice
with 1  phosphate buffered saline (PBS), stained cells were
analyzed by flow cytometry (FACSAria, BD). In all cases, at
least 100,000 eventswere collected for analysis. Each sample
was runwithanappropriate isotypecontrol, and thiswasused
to define the stained cells. Analysis was performed on tightly
gated lymphocytes to exclude dead cells and debris.
Isolation of CMV-specific T cells with streptamer
magnetic beads
The procedure was optimized to isolate CMV-specific CD8þ
T cells from 2  107 PBMCs and performed according to the
manufacturer’s instructions. First, a magnetic streptamer
complex was used to label CMV-specific T cells according to
their antigen specificity. Thereafter bead-labeled cells
were separated from nonspecific cells by a magnetic field.
Later, D-biotin was added to the purified CMV-specific T
cells. Briefly, this process was divided into three steps.
In the first step, 50 mL streptamer magnetic beads were
incubated with 8 mL CMVeMHC and 90 mL IS buffer (IBA
GmbH) overnight at 4C in the dark. Then 1 mL IS buffer was
added to MHC/streptamer magnetic beads solution and
loaded on anmedium scale (MS) column in themagnetic field
to wash unbound MHC and streptamer magnetic beads away.
Therefore, the MS columnwas taken outside of themagnetic
field and the retained beads were firmly flushed out by 250
mL IS buffer using the plunger supplied with the column. A
total of 2 107 cells were gentlymixedwith the 250 mL MHC/
streptamer magnetic beads solution and incubated for
45 minutes at 4C in the dark. These cells were washed and
suspended in 1 mL IS buffer for magnetic separation.
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magnetic field and prepared by rinsing with 3 mL IS buffer,
and the suspended cells above were applied onto the
column, allowing the unlabeled cells to pass through. After
washing three times with 1 mL IS buffer, the MS column was
taken outside of the magnetic field and retained cells were
eluted into a fresh vial by 6 mL IS buffer using the plunger
supplied with the column. Then, the positive cell fraction
was collected for the next step.
In the third and last step, the dissociation of the MHC/
streptamer magnetic beads from the cells was performed
using D-biotin. The fraction of positive cells was centrifuged
and resuspended in 2 mL IS buffer containing 2 mM D-biotin
and incubated on ice for 20 minutes in the dark twice.
Thereafter, the cells were washed with 5 mL IS buffer four
times. Eventually, these cells were collected for further
analysis.
Selection of CMV-specific T cells by tetramer
magnetic beads
After washing with magnetic cell separation (MACS) buffer
(Miltenyi Biotec, Bergisch Gladbach, Germany), HLA-A2þ
cells from peripheral blood samples of healthy donors
were resuspended in 200 mL MACS buffer and incubated
with HLA-A2þ tetramer hCMVpp65 495e503 (NLVPMVATV)
*PE at a concentration of 10 mL per 107 cells for
40 minutes at room temperature in the dark. Cells were
washed twice and resuspended in MACS buffer, and anti-
PE MicroBeads (Miltenyi Biotec) were added at a concen-
tration of 20 mL per 107 cells for 15 minutes at 4C in the
dark. Then, these cells were washed and resuspended in
1 mL MACS buffer for magnetic separation. The MS column
was placed in the magnetic field and prepared by rinsing
with 500 mL MACS buffer, and the resuspended cells above
were applied onto the column, allowing the unlabeled
cells to pass through. After washing with 3  500 mL MACS
buffer, the MS column was taken outside of the magnetic
field. Retained cells were eluted into a fresh vial using 1
mL MACS buffer and the plunger supplied with the
column. The positive fraction was collected for further
analysis.
Carboxyfluorescein succinimidyl ester proliferation
assay
After isolation of CMV-specific CD8þ T cells, CD8 cells
serving as antigen presenting cell (APCs) were irradiated
with 30 Gy and incubated with 20 mg/mL CMV peptide and
2.5 mg/mL b2-microglobulin in 1 mL medium supplemented
with 10% AB medium for 2 hours at 37C. CMV-specific CD8þ
T cells (1  106 cells/mL) were labeled with the vital dye
carboxyfluorescein succinimidyl ester (Invitrogen Gibco,
Grand Island, NY, USA) at a final concentration of 0.5 mM for
15 minutes at 37C and cocultured with CD8 APCs. After
coincubation, mixed lymphocyte peptide culture (MLPC)
was supplemented with 2.5 ng/ml IL-2 and 20 ng/mL IL-7
(Sigma, St. Louis, MO, USA) on dayþ1. After 8 days of
culture, proliferation of CMV-specific CD8þ T cells was
evaluated by fluorescence activated cell sorting (FACS)
analysis as described above.Enzyme-linked immunospot assay
Enzyme-linked immunospot (ELISPOT) assays for inter-
feron (IFN)-gamma and granzyme B were performed as
previously described.13 A total of 4  103 presensitized
CD8þ T lymphocytes and 1  104 target cells [CMVpp65 or
human epidermal growth factor receptor-2 (HER 2)
peptide pulsed T2 cells] were added to each well. Spots
were evaluated using an ELISPOT reader (C.T.L. Ltd, Bonn,
Germany). Results are presented as an average of dupli-
cate cultures.Results
Frequency of CMV-specific CD8D T cells in healthy
donors
In order to select samples with high frequency of CMV-
specific CD8þ T cells, we analyzed 30 peripheral blood
samples from HLA-A2þ/CMV-seropositive healthy donors.
All the samples were analyzed by FACS staining using CMV/
HLA-A2þ CMVpp65 495e503 (NLVPMVATV) streptamers.
Samples from 10 HLA-A2þ but CMV-seronegative healthy
donors were tested as controls, and no CMV-specific CD8þ T
cells were detected (data not shown). In all 30 HLA-A2þ/
CMV-seropositive healthy donors, we were able to detect
CMV-specific CD8þ T cells. The frequency of CD8þ T cells
specifically recognizing the HLA-A2-restricted CMV epitope
ranged from 0.15% to 4.01% when compared to all CD8þ T
cells. In 16 (53.3%) of 30 HLA-A2þ/CMV-seropositive healthy
donors, frequencies of more than 0.5% for CMV-specific
CD8þ T cells were detected when compared to all CD8þ T
cells; in 11 healthy donors we detected frequencies over
1.0% of all CD8þ T cells (Table 1). These samples were used
for further analysis.
Purity of CMV-specific CD8D T cells separated by
CMV streptamer technology
To evaluate the purity of the enriched CMV-specific CD8þ T
cells separated by CMV streptamer magnetic beads, the
positive fraction was stained and analyzed by flow cytom-
etry. After separation of PBMCs, CMV-specific CD8þ T cells
were >90% of the total CD8þ T-cell population; a 35e50-
fold up-concentration of CMV-specific CD8þ T cells could
be achieved, when compared to the total CD8þ T-cell
population (Fig. 1).
Frequency of CMV-specific CD8D T cells purified by
tetramers
In order to evaluate the purity of the CMV-specific CD8þ T
cells selected by tetramers, the positive fraction was
directly analyzed by flow cytometry. After selection of
PBMCs, CMV-specific CD8þ T cells accounted for more than
90% of the total CD8þ T-cell population. Also, here a 30e50-
fold increase in purity could be achieved for CMV-specific
CD8þ T cells when compared to the total CD8þ T-cell pop-
ulation (Fig. 2).
Table 1 Percentage of CD8þ T cells specific for CMV in
HLA-A2þ/CMV-seropositive healthy volunteers.
No. of healthy
volunteers
CMV-specific CD8þ
T cells/CD8þ T cells (%)
1 3.16
2 1.85
3 0.15
4 0.27
5 1.16
6 1.53
7 0.17
8 0.35
9 1.46
10 0.23
11 0.31
12 0.30
13 0.25
14 0.80
15 0.32
16 0.21
17 0.46
18 0.88
19 0.17
20 1.35
21 1.50
22 3.14
23 0.24
24 2.84
25 0.16
26 0.84
27 0.50
28 0.82
29 4.01
30 1.65
CMV Z cytomegalovirus.
Figure 1 Isolation and immunophenotyping of CMV-specific CD8þ
HLA-A2þ/CMV streptamer (PE)-positive CD8þ T lymphocytes (A) be
concentration percentage of HLA-A2þ/CMV streptamer (PE)-positive
CMV streptamer-specific CD8þ T cells were further characteriz
streptamerþCD8þCD45RAþCCR7 T cells in the peripheral blood o
these cells. Panel A (before separation) and Panel B (after separatio
This experiment has been repeated several times with similar resu
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In order to investigate the potential functional status of
CMV-specific CD8þ T cells purified by streptamers and
tetramers, samples of HLA-A2þ/CMV-seropositive healthy
donors before and after separation were identified by
staining for phenotypic markers. CMV-specific CD8þ T cells
before and after separation showed a similar CD antigen
expression (Figs. 1 and 2), with an exception of the increase
in CD28 expression of CMV-specific CD8þ T cells after
streptamer selection. CMV-specific CD8þ T cells stained by
streptamer and tetramer showed a similar frequency of
CD45RAþCCR7 effector T cells. Furthermore CMV-specific
CD8þ T cells, after separation, proved to be almost 100%
CD45RAþ T cells, mostly (80e94%) CCR7eff. T cells (Figs. 1
and 2).
Figs. 1e4 show data from the same sample. Similar data
were obtained from two further samples.
Proliferation of CMV-specific CD8D T cells purified
by tetramer and streptamer technologies
Potential functional characteristics of CMV-specific CD8þ T
cells purified by streptamer and tetramer were further
analyzed by proliferation assays. MLPC followed by multi-
mer (streptamer and tetramer) staining was used to detect
proliferation of CMV-specific CD8þ T-cell populations. The
results showed that 44.1% of CMV-specific CD8þ T cells
purified by streptamer proliferated after 8 days of culture,
and, for the CMV-specific CD8þ T cells purified by tetramer,
the frequency was similar (42.9%) (Fig. 3).
ELISPOT assays for IFN-gamma and granzyme B
Activation of lytic potential of CMVpp65-specific CD8þ Tcells
was assessed by ELISPOT. As shown in combined represen-
tative results from three independent experiments, bothT cells by streptamers. The dot plots show the percentage of
fore and (B) after separation. A 35e50-fold increase in the up-
CD8þ T lymphocytes could be observed after MACS separation.
ed by FACS analysis, demonstrating the existence of CMV-
f healthy donors, thus indicating the effector T-cell status of
n) show a similar immunophenotype of the CMV-specific T cells.
lts. CMV Z cytomegalovirus.
Figure 2 Isolation and immunophenotyping of CMV-specific CD8þ T cells by tetramers. The dot plots show the percentage of HLA-
A2þ/CMV tetramer (PE)-positive CD8þ T lymphocytes (A) before and (B) after separation. For subpopulations of CD8þ T cells,
a 30e50-fold increase in the percentage of HLA-A2/CMV tetramer (PE)-positive CD8þ T lymphocytes could be observed after MACS
separation. CMV tetramer-specific CD8þ T cells were further characterized by FACS analysis, demonstrating the existence of
CD8þCMV-tetramerþCD45RAþCCR7 T cells in the peripheral blood of healthy donors, thus indicating the effector T-cell status of
these cells. Panel A (before separation) and Panel B (after separation) expressed a similar immunophenotype. This experiment has
been repeated several times with similar results. CMV Z cytomegalovirus.
342 X.-C. Wang et al.IFN-gamma (Fig. 4A) and granzyme B (Fig. 4B) were secreted
by either streptamer- or tetramer-selected CMVpp65-
specific CD8þ T cells upon stimulation with the autologous
CD8 APCs pulsed with CMVpp65 peptide. CMVpp65-specific
CD8þ T lymphocytes selected by streptamer beads proved
to be very effective (Fig. 4).
Discussion
Reactivation of CMV constitutes a severe and potentially
life-threatening complication after allo-HSCT. Because ofFluores
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Figure 3 Proliferation characteristics of CMV-specific CD8þ T cell
CMV-specific CD8þ T cells selected by streptamer resulted in a fre
CD8þ T cells purified by tetramers were proliferating after 8 days
proliferation when streptamer- and tetramer-selected CMV-specific
two times with similar results. CMV Z cytomegalovirus.immunosuppression after allo-HSCT, the latent virus can
reactivate, leading to CMV disease. Manifestations of CMV
disease are pneumonia, colitis, and encephalitis.1e3 Prior to
the introduction of antiviral therapy, the frequency of CMV
reactivation was up to 80% of CMV-seropositive allogeneic
recipients and 40% of the patients developed CMV
disease.3,14 The use of antiviral drugs decreased mortality
due to CMV disease after allo-HSCT dramatically.15,16
However, antiviral drugs might cause substantial myelo-
toxicity, resulting in neutropenia and bacterial as well as
fungal infections. CMV reactivation might trigger GVHD.cence
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Figure 4 Specific reactivity of CD8þ T lymphocytes to CMVpp65 peptide assessed by ELISPOT. CMV-specific CD8þ T cells were
isolated by both streptamers and tetramers from a healthy donor and subjected to one round of stimulation with irradiated and
CMVpp65 peptide-loaded CD8 APCs. Their potential to secrete (A) IFN-gamma and (B) granzyme B was measured by ELISPOT assays
employing T2 cells pulsed with CMVpp65 peptide, an irrelevant HLA-A2-restricted HER 2-derived peptide to demonstrate the CMV
specificity of the CD8þ T cells. T2 cells without loading of any peptide were used as negative control. The figure shows one
representative experiment out of three. Error bars indicate the standard deviation. CMV Z cytomegalovirus; ELISPOT Z enzyme-
linked immunospot; HER 2 Z human epidermal growth factor receptor-2; IFN Z interferon.
Streptamer versus tetramer-based selection 343Moreover, CMV can become resistant to antiviral drugs,17
limiting the use of such drugs.
This dilemma has been alleviated by the use of adoptive
transfer of CMV-specific CD8þ T cells. Two strategies have
been described to select CMV-specific CD8þ T cells: First,
CMV-specific CD8þ T-cell clones were cultured from the
transplant donors and infused to the patients after
HSCT7,8,18 or even solid organ transplantation.19 Second,
CMV-specific CD8þ T cells can be directly selected from the
blood of transplant donors and infused into the patients
without ex vivo manipulation.9 CMV-specific CD8þ T-cell
cloning is expensive and demands a cumbersome and
skillful technique, limiting its use to only few specialized
centers of expertise. Therefore, the approach of the
selection of CMV-specific CD8þ T cells directly from the
blood of stem cell transplant donors was recommended by
Cobbold and coworkers9 because of its rather simple
technique and high efficacy.
Our study showed that in all 30 HLA-A2þ/CMV-seroposi-
tive healthy donors, the frequency of CMV-specific CD8þ T
cells, when compared to all CD8þ T cells, ranged from
0.15% to 4.01%. In 11 of 30 HLA-A2þ/CMV-seropositivehealthy donors, more than 1.0% of all CD8þ T cells were
specific for CMVpp65. Gillespie et al20 also reported that
CMV-specific CD8þ T cells range from 0.5% to 4% of the CD8þ
T-cell pool. The data of our present study indicate that we
could select a sufficient number of CMV-specific CD8þ T
cells directly from the blood of healthy donors without
ex vivo manipulation.
With the help of multimer technologies one can identify
and select CMV-specific CD8þ T cells. Therefore, multimers
constitute a benefit for the clinical application of adoptive
CMV-specific CD8þ T-cell transfer.9,10,21 However, multimer
technologies may have some adverse influence on these T
cells. Although Cobbold et al9 reported that use of
HLAepeptide tetramer has a considerable potential for
antigen-specific CD8þ T-cell therapy, Neudorfer et al stated
that regarding the selection of antigen-specific CD8þ T cells
for clinical application, the reversible streptamer tech-
nique might be favorable when compared to the tetramer
method. Therefore, the approach for the selection of CMV-
specific CD8þ T cells directly from the blood of healthy
donors by both multimer technologies (tetramer and
streptamer) was assessed in the present study.
344 X.-C. Wang et al.A 30e50-fold increase in purity of specific CD8þ T cells
could be achieved through the selection by both tetramer
and streptamer technologies when compared to total CD8þ
T-cell population. The purity that we could achieve in this
study was more than 90% for both methods. The difference
of both multimer technologies is that CMV-specific CD8þ T-
cell selection by streptamer technology was followed by
a dissociation of streptamer with D-biotin, thus avoiding
potential side effects resulting from the multimer reagents
and allowing the selection of antigen-specific CD8þ T cells
with preserved, naı¨ve function.10 Streptamer-coated beads
can be detached following selection, which is in accordance
with the guidelines. Therefore, bead-conjugated strep-
tamers constitute a further development of good
manufacturing practice (GMP) of the currently used
tetramer-based selection methods.9e11
The functional status of CMV-specific CD8þ T cells
selected by streptamers and tetramers was identified by
the staining of phenotypic markers. On the basis of CD45RA
and CCR7 expression, CD8þ T cells can be dissected into
four groups: naı¨ve (N: CD45RAþCCR7þ), effector (E:
CD45RAþCCR7), central memory (CM: CD45RACCR7þ),
and effector memory (EM: CD45RACCR7) T cells.22
Different states of CD8þ T-cell activation imply different
functional and immunophenotypic characteristics. We
performed staining with anti-CD69 as a marker of activation
of T cells as well as with CD107a as a marker of intracellular
granzyme B. CD137 was used as another activation marker,
and staining against CD28 was performed to distinguish
early and late effector memory cells.22 In this study, we
found that CMV-specific CD8þ T cells identified by tetramer
and streptamer technologies before and after separation
were consistently CD8þCMV-multimerþCD45RAþCCR7 T
cells. The ratio of CMV-specific CD8þ T cells was more than
90% of all CD8þ T cells after selection. Our results indicate
that most selected CMV-specific CD8þ T cells have an
effector T-cell immunophenotype, and the functional
status of CD8þ T cells might be preserved. One exception
was the increase in CD28 expression of CMV-specific CD8þ T
cells after streptamer selection. This might indicate
a further positive activation of these specific T cells.22
Regarding the proliferation of CMV-specific CD8þ T cells,
the results showed that 44.1% of these T cells purified by
streptamer proliferated after 8 days of culture, and for the
T cells purified by tetramer, the frequency was 42.9%. The
results showed a significant proliferation when CMV-specific
CD8þ T cells selected by both streptamer and tetramer
technologies were cultured. However, the functional status
of tetramer-selected CMV-specific CD8þ T cells might be
altered by the persistent binding of tetramer reagents. This
might also be the reason for the somewhat altered pattern
of the curve in the Carboxyfluorescein succinimidyl ester
(CSFE) staining (Fig. 3). The functional activity of tetramer-
labeled CMV-specific CD8þ T cells could also be hampered
by the persistence of TCReMHC interactions resulting from
tetramer and subsequently induced signaling events.23,24 In
this study, we could clearly demonstrate, by ELISPOT
assays, that streptamer-selected CMV-specific CD8þ T cells
are active (secretion of IFN-gamma) and that they are
cytotoxic (secretion of granzyme B). As streptamer
reagents could be detached from the isolated CMV-specific
CD8þ T cells, several side effects caused by reagents mightbe avoided, including T-cell anergy, harm for clinical in vivo
application, immune responses directly against the
reagents, and loss of the capacity of the transferred T cells
to migrate in vivo. This indicates that the streptamer
technology might constitute a step further in the develop-
ment of multimers for adoptive T-cell therapy.25
In summary, the multimer technology comprising both
streptamers and tetramers constitutes an interesting novel
tool for further adoptive transfer of CMV-specific CD8þ T
cells. Moreover, the streptamer technology is available at
GMP level, thus allowing the (“reversible”) selection of
CMV-specific CD8þ T cells while preserving their function.Competing Interests
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